This AI Company Is Solving a 100+ Year-Old Health Problem

This is sponsored content. Barchart is not endorsing the websites or products set forth below.

Heart disease has been the leading cause of death worldwide since 1921. And to this very day, electrocardiograms (ECGs) – the most common cardiac test in the world used throughout healthcare – cannot detect most forms of heart disease until its too late. 

Led by a group of executives with strong track records and technology developed with backgrounds at St. Jude, Mount Sinai Hospital, and Rutgers Hospital among others, HeartSciences is solving this problem. With AI-powered ECG technology, they’re aiming to help frontline medical professionals detect a broad range of heart disease and do it earlier than ever. 

Here’s how HeartSciences is changing the future of cardiac care—and why now is the time to invest.

HeartSciences’ $30B Market Revolution

Cardiac diagnostics is a massive and growing space. More than 1 billion ECGs are performed annually around the world, and most of them still rely on decades-old technology. This opens up a huge opportunity for HeartSciences in the $30B heart healthcare opportunity. 

The company is bringing ECGs into the AI era, offering AI-enhanced ECGs that interact with a secure cloud platform to gather insights. Here is their product pipeline: 

• MyoVista® wavECG™ – A next-gen device that delivers embedded AI-enhanced ECG readings at the point of care.
• MyoVista® Insights™ – A secure cloud platform built to scale, offering an "app store" for AI-ECG algorithms for the millions of ECGs already in use today.

Providing a dual solution means they will be able to deliever AI-ECG in any healthcare environment worldwide and should provide them a greater potential market share. Plus, they have the ability to expand to consumer products, telehealth, and wearable integrations down the road.

With that and 43 patents protecting their technology, HeartSciences is set up to be a  first-mover in their industry.

HeartSciences’ Recurring Revenue Model

Because HeartSciences offers a comprehensive suite of tools for heart disease detection and insights, they have the potential for multiple streams of recurring revenue, from “razorblade” sales to subscriptions: 

• Device + Consumables – A razor-razorblade model with high-margin per-test revenue.
• SaaS + Cloud Licensing – Subscription and per-use pricing for AI-ECG algorithms.

Working to solve one of the world’s biggest health crises while establishing a high-powered business - would be a unique feat for HeartSciences And you now have a chance to be part of their journey.

Why Now Is the Time to Invest

While HeartSciences is publicly traded on Nasdaq under HSCS, investors get a chance to own two shares of common stock by participating in their current round. For $3.50/unit, you receive:

• 1 Share of Preferred Stock (convertible to 1 share of common stock)
• 1 Warrant to purchase an additional share of common stock

That’s two shares per unit. 

With FDA clearance targeted in 2025, Medicare reimbursement already in place, and a product built for global scale, we believe that HeartSciences is at an inflection point—making now an exciting time to become a HeartSciences shareholder.

Disclosure: This is a paid advertisement for HeartSciences’  Regulation A Offering. Additional information on the company and risk factors related to the offering can be found in the prospectus supplement and accompanying base prospectus has been filed with the SEC. A copy of the Final Offering Circular that forms a part of the Offering Statement may be obtained from: Offering Circular

HeartScience's Regulation A+ offering is made available through DealMaker Securities, LLC, a FINRA/SIPC registered broker-dealer (“DealMaker” or “Broker”) and its affiliates. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment. For more information about this offering, including certain material risks associated with it, please view HeartScience's latest offering circular (SEC Form 253G2). Dealmaker may compensate Barchart up to eight thousand dollars for the placement and promotion of the content on this site and other forms of public distribution covering the period of March 25th.